Intest Res.
2009 Dec;7(2):135-136.
Influence of Trough Serum Levels and Immunogenicity onLong-term Outcome of Adalimumab Therapy in Crohn's Disease(Gastroenterology 2009;137:1628-1640)
- Affiliations
-
- 1Digestive Disease Research Institute, Department of Internal Medicine,College of Medicine, Wonkwang University, Iksan, Korea. medsgs@wonkwang.ac.kr
Abstract
- No abstract available.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab
- Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center Study
- Eruptive Benign Melanocytic Nevi Formation Following Adalimumab Therapy in a Patient with Crohn's Disease
- Pulmonary Extraintestinal Manifestation of Crohn's Disease Treated Successfully with Adalimumab
- Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
